Skip to main content

Advertisement

SpringerLink
Log in

Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers

  • Original Articles
  • Published:
International journal of pancreatology Aims and scope Submit manuscript

Summary

Pancreatic cancer is a devastating disease with poor survival. At present, no effective adjuvant or palliative therapies are available. Unresponsiveness to chemotherapy, radiotherapy, and antihormonal treatment is one of the reasons that pancreatic cancer patients have an overall median survival time of 4–6 mo. This article summarizes clinical trials on immunotherapy of pancreatic cancer using the murine monoclonal antibodies (MAbs) 17-1A and BW 494. In addition, the use of MAb treatment in combination with immune response modifiers is discussed. In four clinical trials, MAb 17-1A was given by iv infusion to 100 patients with pancreatic cancer. In 30 of these patients, antibody treatment was accompanied, by γ-interferon, also given intravenously. Complete response, partial response, and stable disease were reported in 1, 5, and 23 patients, respectively. Passive immunotherapy using the MAb BW 494 was carried out in 148 pancreatic cancer patients in two phase I and two phase II trials. In 1 out of 75 patients a partial response and in 25 out of 74 paitents stable disease were reported. However, in a controlled, randomized trial enrolling, 61 patients following Whipple resection, comparable survival times in patients with, and without MAb BW 494 treatment led to the termination of further clinical trials with this antibody. New clinical studies using humanized MAbs in combination with immune response modifiers should be initiated to, further evaluate immunotherapy as a treatment option in pancreatic cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Silverberg E, Lubera JA. Cancer statistics, 1989.Ca Can J Clin 1989; 39: 3–20.

    Article  CAS  Google Scholar 

  2. Gudjonsson B. Cancer of the pancreas: 50 years of surgery.Cancer 1987; 60: 2284–2303.

    Article  PubMed  CAS  Google Scholar 

  3. Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.Cancer 1991; 68: 965–969.

    Article  PubMed  CAS  Google Scholar 

  4. Topham C, Glees J Rawson NS, Woods EM, Coombes RC. Randomized trial of epirubicin alone versus 5-fluorouracil, epirubicin and mitomycin C in locally advanced and metastatic carcinoma of the pancreas.Br J Cancer 1991; 64: 179–181.

    PubMed  CAS  Google Scholar 

  5. Tennvall J, Ljungberg O, Ahren B, Gustavsson A, Nillson LO. Radiotherapy for unresectable endocrine pancreatic carcinomas.Eur J Surg Oncol 1992; 18: 73–76.

    PubMed  CAS  Google Scholar 

  6. Komaki R, Wadler S, Peters T, Byhardt RW, Order S, Gallagher MJ, Herskovic A, Pederson J. High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group Protocol 8801).Cancer 1992; 69: 2807–2812.

    Article  PubMed  CAS  Google Scholar 

  7. Schifeling DJ, Konski AA, Howard JM, Dobelbower RR Jr, Merrick HW 3rd, Skeel RT. Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas: a phase I study.Int J Pancreatol 1992; 12: 239–243.

    PubMed  CAS  Google Scholar 

  8. Friess H, Büchler M, Krüger M, Beger, HG. Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin.Pancreas 1992; 7: 516–521.

    PubMed  CAS  Google Scholar 

  9. Friess H, Büchler M, Beglinger, Ch, Weber A, Kunz J, Fritsch K, Beger HG. Low dose octreotide treatment is not effective in patients with advanced pancreatic cancer.Pancreas 1993; 8: 540–545.

    Article  PubMed  CAS  Google Scholar 

  10. Friess H, Büchler MW, Ebert M, Malfertheiner P, Dennler HJ, Beger HG. Treatment of advanced pancreatic cancer with high dose octreotide.Int J Pancreatol 1993; 14: 290,291.

    PubMed  CAS  Google Scholar 

  11. Bramhall SR, Neoptolemos JP. Role of adjuvant chemo-and radiotherapy in pancreatic cancer.Dig Surg 1994; 11: 408–413.

    Article  Google Scholar 

  12. Watanapa P, Williamson RC. Surgical palliation for pancreatic cancer: developments during the past two decades.Br J Surg 1992; 79: 8–20.

    Article  PubMed  CAS  Google Scholar 

  13. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Büchler M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increase in the levels of epidermal growth factor and transforming growth factor alpha.J Clin Invest 1992; 90: 1352–1360.

    Article  PubMed  CAS  Google Scholar 

  14. Yamanaka Y, Friess H, Kobrin MS, Büchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness.Anticancer Res 1993; 13: 565–570.

    PubMed  CAS  Google Scholar 

  15. Yokoyama M, Ebert M, Funatomi H, Friess H, Büchler MW, Johnson GR, Korc M. Amphiregulin is a potent mitogen in human pancreatic cancer cells: correlation with patients' survival.Int J Oncol 1995; 6: 625–631.

    Google Scholar 

  16. Yamanaka Y, Friess H, Büchler MW, Beger HG, Uchida E, Masahiko O, Kobrin MS, Korc M. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage.Cancer Res 1993; 53: 5289–5296.

    PubMed  CAS  Google Scholar 

  17. Friess H, Yamanaka Y, Büchler MW, Ebert M, Beger HG, Gold LI, Korc M. Enhanced expression of transforming growth factor-beta isoforms in pancreatic cancer correlates with decreased survival.Gastroenterology 1993; 105: 1846–1856.

    PubMed  CAS  Google Scholar 

  18. Friess H, Yamanaka Y, Büchler MW, Beger HG, Kobrin MS, Baldwin RL, Korc M. Enhanced expression of the type II transforming growth factor-beta receptor in human pancreatic cancer cells without alteration of type III receptor expression.Cancer Res 1993; 53: 2704–2707.

    PubMed  CAS  Google Scholar 

  19. Yamanaka Y, Friess H, Büchler MW, Kobrin MS, Kunz J, Beger HG, Korc M. Overexpression of HER2/neu oncogene in human pancreatic carcinoma.Hum Pathol 1993; 24: 1127–1134.

    Article  PubMed  CAS  Google Scholar 

  20. Korc M, Yokoyama M, Friess H. HER2/neu immunostaining in pancreatic carcinoma.Hum Pathol 1994; 25: 5.

    Article  Google Scholar 

  21. Friess H, Yamanaka Y, Korc M, Büchler MW. Overexpression of c-erbB-3 in human pancreatic cancer: correlation with tumor aggressiveness.Digestion 1994; 55: 59,299.

    Article  Google Scholar 

  22. Ebert M, Yokoyama M, Friess H, Büchler MW, Korc M. Coexpression of thec-met protooncogene and hepatocyte growth factor in human pancreatic cancer.Cancer Res 1994; 54: 5775–5778.

    PubMed  CAS  Google Scholar 

  23. Grünewald K, Lyons J, Fröhlich A, Feichtinger H, Weger RA, Schwab G, Janssen JWG, Bartram CR. High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas.Int J Cancer 1989; 43: 1037–1041.

    Article  PubMed  Google Scholar 

  24. Barton CM, Staddon SL, Hughes CM, Hall PA, O'Sullivan C, Kloppel G, Theis B, Russell RCG, Neoptolemos J, Williamson RCN, Lane DP, Lemoine NR. Abnormalities of the p53 tumor suppressor gene in human pancreatic cancer.Br J Cancer 1991; 64: 1076–1082.

    PubMed  CAS  Google Scholar 

  25. Casey G, Yamanaka Y, Friess H, Kobrin MS, Lopez ME, Büchler M, Beger HG, Korc M. p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis.Cancer Lett 1993; 69: 151–160.

    Article  PubMed  CAS  Google Scholar 

  26. Tempero MA, Pour PM, Uchida E, Herlyn D, Steplewski Z. Monoclonal antibody CO 17-1A and leukopheresis in immunotherapy of pancreatic cancer.Hybridoma 1986; 5: 133–138.

    Google Scholar 

  27. Sindelar WF, Maher MM, Herlyn D, Sears HF, Steplewski Z, Koprowski H. Trial of therapy with monoclonal antibody 17-1A in pancreatic carcinoma: preliminary results.Hybridoma 1986; 5(Suppl 1): 125–132.

    Google Scholar 

  28. Tempero MA, Sivinski CL, Steplewski Z, Harvey E, Klassen L, Kay HD. Phase II trial of gamma interferon and monoclonal antibody 17-1A in pancreatic cancer biological and clinical effects.J Clin Oncol 1990; 8: 2019–2026.

    PubMed  CAS  Google Scholar 

  29. Tempero MA, Haga Y, Sivinski C, Steplewski Z, Kay HD, Pour P. Immunotherapy with monoclonal antibody (MAB) in pancreatic adenocarcinoma.Int J Pancreatol 1991; 9: 125–134.

    PubMed  CAS  Google Scholar 

  30. Weiner LM, Harvey E, Padavic-Shaller K, Willson JK, Walsh C, LaCreta F, Khazaeli MB, Kirkwood JM, Haller DG. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma.J Immunother 1993; 13: 110–116.

    Article  CAS  Google Scholar 

  31. Büchler M, Kübel R, Malfertheiner P, Friess H, Schulz G, Bosslet K, Beger HG. Immunotherapy of advanced pancreatic carcinoma with the monoclonal antibody BW 494.Deutsche Medizinische Wochenschrift 1988; 113: 374–380.

    Article  PubMed  Google Scholar 

  32. Büchler M, Friess H, Malfertheiner P, Schultheiss KH, Muhrer KH, Kraemer HP, Beger HG. Studies of pancreatic cancer utilizing monoclonal antibodies.Int J Pancreatol 1990; 7: 151–157.

    PubMed  Google Scholar 

  33. Büchler M, Friess H, Schultheiss KH, Gebhardt Ch, Kübel R, Muhrer KH, Winkelmann M, Wagener Th, Klapdor R, Kaul M, Müller G, Schulz G, Beger HG. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.Cancer 1991; 68: 1507–1512.

    Article  PubMed  Google Scholar 

  34. Büchler M, Kübel R, Klapdor R, Muhrer KH, Friess H, Lorenz B, Schulz G, Bosslet K, Beger HG. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494: Results from a multicentric phase I–II trial, inCancer Therapy, Beger HG, Büchler M, Schulz G, Reisfeld R, eds., Springer, Berlin Heidelberg, 1989; pp. 32–41.

    Google Scholar 

  35. Friess H, Büchler M, Schulz G, Beger HG. Therapy of pancreatic carcinoma with the monoclonal antibody BW 494/32: first clinical results.Immunität und Infektion 1989; 17: 24–26.

    PubMed  CAS  Google Scholar 

  36. Schulz G, Büchler M, Muhrer KH, Klapdor R, Kubel R, Harthus HP, Madry N, Bosslet K. Immunotherapy of pancreatic cancer with monoclonal antibody BW 494.Int J Cancer 1988; 2: 89–94.

    Article  CAS  Google Scholar 

  37. Koprowski H, Steplewski Z, Mitchel K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma detected by hybridoma antibodies.Somat Cell Genet 1979; 5: 957–972.

    Article  PubMed  CAS  Google Scholar 

  38. Steplewski Z, Lubeck MD, Koprowski H. Human macrophages armed with murine IgG2a anti-tumor immunoglobulin destroy human cancer cells.Science 1983; 221: 865–867.

    Article  PubMed  CAS  Google Scholar 

  39. Gottlinger H, Funke J, Johnson JP, Gokel JM, Reithmüller G. The epithelial cell surface antigen 17-1A, a target for antibody mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies.Int J Cancer 1986; 38: 47–53.

    Article  PubMed  CAS  Google Scholar 

  40. Sears HF, Steplewski Z, Herlyn D, Koprowski H. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma.J Biol Resp Mod 1984; 3: 138–150.

    CAS  Google Scholar 

  41. Adams DO, Hall T, Steplewski Z, Koprowski H. Tumors undergoing regression induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-cytolysis.Proc Natl Acad Sci USA 1984; 81: 3506–3510.

    Article  PubMed  CAS  Google Scholar 

  42. Bosslet K, Kern HF, Kanzy EJ, Steinstraesser A, Schwarz A, Luben G, Schorlemmer HU, Sedlacek HH. A monoclonal antibody with binding and inhibiting activity towards human pancreatic carcinoma cells. I: Immunohistological and immunochemical characterization of a murine monoclonal antibody selecting for well differentiated adenocarcinomas of the pancreas.Cancer Immunol Immunother 1986; 23: 185–191.

    Article  PubMed  CAS  Google Scholar 

  43. Kübel R, Büchler M, Baczko K, Beger HG. Immunohistochemistry in pancreatic cancer with new monoclonal antibodies.Lang Arch Chir 1987; 371: 243–252.

    Article  Google Scholar 

  44. Montz R, Klapdor R, Rothe B, Heller M. Immunoscintigraphy and radioimmunotherapy in patients with pancreatic carcinoma.Nuklearmedizin 1986; 25: 239–244.

    PubMed  CAS  Google Scholar 

  45. Kern HF, Bosslet K, Mollenhauer J, Sedlacek HH, Schorlemmer HU. Monocyte-related functions expressed in cell lines established from human pancreatic adenocarcinoma. I: Comparative analysis of endocytotic activity, lysosomal enzyme secretion, and superoxide anion production.Pancreas 1987; 2: 212–221.

    Article  PubMed  CAS  Google Scholar 

  46. Kern HF, Bosslet K, Sedlacek HH, Schorlemmer HU. Monocyte-related functions expressed in cell lines established from human pancreatic adenocarcinoma. II. Inhibition of stimulated activity by monoclonal antibodies reacting with surface antigens on tumor cells.Pancreas 1988; 3: 2–10.

    Article  PubMed  CAS  Google Scholar 

  47. Klapdor R, Lander S, Bahlo M, Montz R. Radioimmunotherapy of xenografts of human pancreatic carcinomas-intravenous and intratumoral application of 1311-labeled monoclonal antibodies.Nuklearmedizin 1986; 25: 235–238.

    PubMed  CAS  Google Scholar 

  48. Hermanek P, Scheibe O, Spiessl B, Wagner G.TNM Klassifikation maligner Tumoren, Springer, Berlin, 1987.

    Google Scholar 

  49. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma.Cancer Res 1985; 45: 5910–5913.

    PubMed  CAS  Google Scholar 

  50. Herlyn D, Koprowski H. IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells.Proc. Natl Acad Sci USA 1982; 79: 4761–4765.

    Article  PubMed  CAS  Google Scholar 

  51. Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody.Cancer Res 1980; 40: 717–721.

    PubMed  CAS  Google Scholar 

  52. Houghton AN, Mintzer D, Cordon-Cardo C, Weltm S, Fliegel B, Vadhan S, Carswell E, Melamed MR, Oettgen HF, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma.Proc Natl Acad Sci USA 1985; 82: 1242–1246.

    Article  PubMed  CAS  Google Scholar 

  53. Bosslet K, Döring N, Seemann G, Schulz G, Sedlacek HH. Immunological tailoring of monoclonal antibodies for immunotherapy of pancreatic carcinoma.Int J Cancer 1988; 2: 85–88.

    Article  CAS  Google Scholar 

  54. Herlyn D, Wettendorff M, Schmoll E, Iliopoulos D, Schedel I, Dreikhausen U, Raab R, Ross AH, Jaksche H, Scriba M. Anti-idiotype immunization of cancer patients: modulation of the immune response.Proc Natl Acad Sci USA 1987; 84: 8055–8059.

    Article  PubMed  CAS  Google Scholar 

  55. Herlyn D, Ross AH, Koprowski H. Anti-idiotypic antibodies bear the internal image of a human tumor antigen.Science 1986; 232: 100–102.

    Article  PubMed  CAS  Google Scholar 

  56. Wettendorff M, Iliopoulos D, Tempero M, Kay D, DeFreitas E, Koprowski H, Herlyn D. Idiotypic cascades in cancer patients treated with monoclonal antibody C017-1A.Proc Natl Acad Sci USA 1989; 86: 3787–3791.

    Article  PubMed  CAS  Google Scholar 

  57. Herlyn D, Sears H, Iliopoulos D, Lubeck M, Douillard JY, Sindelar W, Tempero M, Mellstedt H, Maher M, Koprowski H. Anti-idiotypic antibodies to monoclonal antibody CO17-1A.Hybridoma 1986; 5: 51–58.

    Google Scholar 

  58. Kennedy RC, Zhou EM, Lanford RE, Chanh TC, Bona CA. Possible role of anti-idiotypic antibodies in the induction of tumor immunity.J Clin Invest 1987; 80: 1217–1224.

    Article  PubMed  CAS  Google Scholar 

  59. Bosslet K, Keweloh HC, Hermentin P, Muhrer KH, Sedlacek HH, Schulz G. Percolation and binding of monoclonal antibody BW494 to pancreatic carcinoma tissues during high dose immunotherapy and consequences for future therapy modalities.Br J Cancer 1990; 10: 37–39.

    CAS  Google Scholar 

  60. Goodman GE, Hellstrom I, Yelton DE, Murray JL, O'Hara S, Meaker E, Zeigler L, Palazollo P, Nicaise C, Usakewicz J. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancer.Cancer Immunol Immunother 1993; 36: 267–273.

    Article  PubMed  CAS  Google Scholar 

  61. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma.Blood 1989; 73: 1936–1941.

    PubMed  CAS  Google Scholar 

  62. Senter PD. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy.FASEB J 1990; 4: 188–193.

    PubMed  CAS  Google Scholar 

  63. Svensson HP, Kadow JF, Vrudhula VM, Wallace PM, Senter PD. Monoclonal antibody-beta-lactamase conjugates for the activation of a cephalosporin mustard prodrug.Bioconjugate Chem 1992; 3: 176–181.

    Article  CAS  Google Scholar 

  64. Senter PD, Wallace PM, Svensson HP, Kerr DE, Hellstrom I, Hellstrom KE. Activation of prodrugs by antibody-enzyme conjugates.Adv Exp Med Biol 1991; 303: 97–105.

    PubMed  CAS  Google Scholar 

  65. Stalb L, Link KH, Mitchell MS. Immunomodulation of pancreatic cancer in vitro. Effect of monoclonal antibodies, GM-CSF and lymphokine-activated killer cells.Digestion 1992; 52: 124.

    Google Scholar 

  66. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegei W, Raab R, Hoffken K, Gruber R, Pichimaier H, Hirche H, Pichimayr R. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal carcinoma.Lancet 1994; 343: 1177–1183.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Visceral and Transplantation Surgery, University of Bern, Inseispital, CH-3010, Bern, Switzerland

    Helmut Friess, Michael Gassmann & Markus W. Büchler

Authors
  1. Helmut Friess
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Gassmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Markus W. Büchler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Friess, H., Gassmann, M. & Büchler, M.W. Adjuvant therapy of pancreatic cancer using monoclonal antibodies and immune response modifiers. Int J Pancreatol 21, 43–52 (1997). https://doi.org/10.1007/BF02785919

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02785919

Key Words

Search

Navigation